Crouse J R, Grundy S M
Metabolism. 1981 Feb;30(2):123-8. doi: 10.1016/0026-0495(81)90160-8.
To evaluate the effectiveness of colestipol and clofibrate in patients with hypercholesterolemia and normal concentrations of triglycerides, 27 patients were randomized into three groups, and colestipol, clofibrate, and avicel powder placebo were compared for effects on concentration of total plasma lipid and lipoprotein cholesterol and triglyceride in a single blind protocol over 8 mo. Mean pretreatment values for low density lipoprotein (LDL)-cholesterol and very low density lipoprotein (VLDL) triglyceride were 250 mg/dl and 68 mg/dl, respectively. Colestipol (30 g/day) lowered total- and LDL-cholesterol by 25% and 31%k, respectively, while VLDL-triglyceride rose. Overall clofibrate lowered total- and LDL-cholesterol by 13% and 12% while lowering VLDL-triglyceride 21% and VLDL cholesterol by 50%. For clofibrate, certain patients showed a more pronounced effect than others: in seven of nine patients clofibrate lowered both mean total- and LDL-cholesterol by 17% (range 8% to 31%) and 19% (range 10%--44%) respectively, whereas two patients did not respond to clofibrate. High density lipoproteins were not affected by either colestipol or clofibrate in these patients. Thus, while colestipol was more consistently effective, certain hypercholesterolemic patients responded equally well to clofibrate with substantial lowering of total-, LDL-, and VLDL-cholesterol.
为评估考来烯胺和氯贝丁酯对高胆固醇血症且甘油三酯浓度正常患者的疗效，将27例患者随机分为三组，采用单盲方案，比较考来烯胺、氯贝丁酯和微晶纤维素粉安慰剂在8个月内对总血浆脂质、脂蛋白胆固醇和甘油三酯浓度的影响。低密度脂蛋白（LDL）胆固醇和极低密度脂蛋白（VLDL）甘油三酯的平均治疗前值分别为250mg/dl和68mg/dl。考来烯胺（30g/天）使总胆固醇和LDL胆固醇分别降低25%和31%，而VLDL甘油三酯升高。总体而言，氯贝丁酯使总胆固醇和LDL胆固醇降低13%和12%，同时使VLDL甘油三酯降低21%，VLDL胆固醇降低50%。对于氯贝丁酯，部分患者的效果比其他患者更显著：在9例患者中的7例，氯贝丁酯使平均总胆固醇和LDL胆固醇分别降低17%（范围8%至31%）和19%（范围10%至44%），而2例患者对氯贝丁酯无反应。这些患者的高密度脂蛋白不受考来烯胺或氯贝丁酯的影响。因此，虽然考来烯胺的疗效更稳定，但某些高胆固醇血症患者对氯贝丁酯的反应同样良好，可使总胆固醇、LDL胆固醇和VLDL胆固醇大幅降低。
